Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Modified Lemaire extra-articular stabilisation of the knee for the treatment of anterolateral instability combined with diffuse pigmented villonodular synovitis: a case report.

Farthing C, Lang G, Feucht MJ, Südkamp NP, Izadpanah K.

BMC Musculoskelet Disord. 2018 Sep 11;19(1):330. doi: 10.1186/s12891-018-2248-7.

2.

Determination of l-glutamic acid and γ-aminobutyric acid in mouse brain tissue utilizing GC-MS/MS.

Farthing CA, Farthing DE, Gress RE, Sweet DH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:64-70. doi: 10.1016/j.jchromb.2017.10.020. Epub 2017 Oct 9.

PMID:
29031110
3.

AOAC SMPR® 2017.012. Standard Method Performance Requirements (SMPRs) for Quantitation of Select Nonvolatile Ginger Constituents.

Bzhelyansky A, Atkinson G, Brown L, Burns P, Es-Safi NE, Farthing C, Horkey A, Johnson H, Kuszak A, Lippert A, Mudge E, Phillips T, Reif K, Rimmer C, Solyom A, Szpylka J, Travis J, Yang J, You H, Young K, Coates S.

J AOAC Int. 2017 Jul 1;100(4):1192-1196. doi: 10.5740/jaoacint.SMPR2017_012. No abstract available.

PMID:
28802314
4.

AOAC SMPR® 2017.011. Standard Method Performance Requirements (SMPRs) for Identification and Quantitation of Free Alpha Amino Acids in Dietary Ingredients and Supplements.

Zielinski G, Atkinson G, Bhandari SD, Burns P, Citrolo D, Farthing C, Glover B, Horkey A, Johnson HE, Kuszak A, Lin J, Lippert JA, Mudge E, Ofitserova M, Reimann LM, Solyom AM, Sullivan DM, Szpylka J, Travis J, Wubben JL, Yang J, You H, Young K, Coates SG.

J AOAC Int. 2017 Jul 1;100(4):1189-1191. doi: 10.5740/jaoacint.SMPR2017_011. Epub 2017 Jul 21. No abstract available.

PMID:
28730972
5.

Inosine and hypoxanthine as novel biomarkers for cardiac ischemia: from bench to point-of-care.

Farthing DE, Farthing CA, Xi L.

Exp Biol Med (Maywood). 2015 Jun;240(6):821-31. doi: 10.1177/1535370215584931. Epub 2015 May 8. Review.

6.

Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis.

Fowler AA 3rd, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, Farthing CA, Larus TL, Martin E, Brophy DF, Gupta S; Medical Respiratory Intensive Care Unit Nursing, Fisher BJ, Natarajan R.

J Transl Med. 2014 Jan 31;12:32. doi: 10.1186/1479-5876-12-32.

7.

Expression and function of organic cation and anion transporters (SLC22 family) in the CNS.

Farthing CA, Sweet DH.

Curr Pharm Des. 2014;20(10):1472-86. Review.

PMID:
23789957
8.

Epidemiology of HIV infection among men having sex with men in Shanghai, China.

Zheng Y, Lu H, Jiang X, Pang M, Farthing C.

Southeast Asian J Trop Med Public Health. 2012 Sep;43(5):1304-6. No abstract available.

PMID:
23431841
9.

Study on clinical epidemiology of male HIV/AIDS patients in a tertiary Chinese hospital, Shanghai, China.

Zheng Y, Lu H, Jiang X, Pang M, Farthing C.

Public Health. 2013 Jan;127(1):76-8. doi: 10.1016/j.puhe.2012.09.007. Epub 2012 Nov 17. No abstract available.

PMID:
23164611
10.

A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma.

Farthing CA, Farthing DE, Koka S, Larus T, Fakhry I, Xi L, Kukreja RC, Sica D, Gehr TW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Oct 15;878(28):2891-5. doi: 10.1016/j.jchromb.2010.07.022. Epub 2010 Aug 3.

11.

A rapid and simple chemiluminescence method for screening levels of inosine and hypoxanthine in non-traumatic chest pain patients.

Farthing DE, Sica D, Hindle M, Edinboro L, Xi L, Gehr TW, Gehr L, Farthing CA, Larus TL, Fakhry I, Karnes HT.

Luminescence. 2011 Jan-Feb;26(1):65-75. doi: 10.1002/bio.1187. Epub 2009 Dec 16.

PMID:
20017127
12.

Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.

Grant P, Taylor J, Cain P, Short W, Gallant J, Farthing C, Thal G, Coakley E, Zolopa A.

Clin Infect Dis. 2009 Mar 1;48(5):680-2. doi: 10.1086/597008.

PMID:
19191657
13.

Cellular nonmuscle myosins NMHC-IIA and NMHC-IIB and vertebrate heart looping.

Lu W, Seeholzer SH, Han M, Arnold AS, Serrano M, Garita B, Philp NJ, Farthing C, Steele P, Chen J, Linask KK.

Dev Dyn. 2008 Dec;237(12):3577-90. doi: 10.1002/dvdy.21645.

14.

An in vivo-in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis.

Maynor LM, Carl DE, Matzke GR, Gehr TW, Farthing C, Farthing D, Brophy DF.

Pharmacotherapy. 2008 Aug;28(8):977-83. doi: 10.1592/phco.28.8.977.

PMID:
18657014
15.

An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults.

Levine AJ, Hinkin CH, Ando K, Santangelo G, Martinez M, Valdes-Sueiras M, Saxton EH, Mathisen G, Commins DL, Moe A, Farthing C, Singer EJ.

J Clin Exp Neuropsychol. 2008 Oct;30(7):836-43. doi: 10.1080/13803390701819036. Epub 2008 Feb 8.

16.

Global mapping of DNA methylation in mouse promoters reveals epigenetic reprogramming of pluripotency genes.

Farthing CR, Ficz G, Ng RK, Chan CF, Andrews S, Dean W, Hemberger M, Reik W.

PLoS Genet. 2008 Jun 27;4(6):e1000116. doi: 10.1371/journal.pgen.1000116.

17.

Epiblastic Cited2 deficiency results in cardiac phenotypic heterogeneity and provides a mechanism for haploinsufficiency.

MacDonald ST, Bamforth SD, Chen CM, Farthing CR, Franklyn A, Broadbent C, Schneider JE, Saga Y, Lewandoski M, Bhattacharya S.

Cardiovasc Res. 2008 Aug 1;79(3):448-57. doi: 10.1093/cvr/cvn101. Epub 2008 Apr 25.

18.

Effects of salicylic acid on post-ischaemic ventricular function and purine efflux in isolated mouse hearts.

Farthing D, Gehr L, Karnes HT, Sica D, Gehr T, Larus T, Farthing C, Xi L.

Biomarkers. 2007 Nov-Dec;12(6):623-34.

PMID:
17852081
19.

Peripheral Neuropathy Induced by Lopinavir-Saquinavir-Ritonavir Combination Therapy in an HIV-Infected Patient.

Khanlou H, Valdes-Sueiras M, Farthing C.

J Int Assoc Physicians AIDS Care (Chic). 2007 Sep;6(3):155. No abstract available.

PMID:
17766779
20.

Results of an Antiretroviral Adherence Intervention: STAR (Staying Healthy: Taking Antiretrovirals Regularly).

Murphy DA, Marelich WD, Rappaport NB, Hoffman D, Farthing C.

J Int Assoc Physicians AIDS Care (Chic). 2007 Jun;6(2):113-24.

PMID:
17538003
21.

An HPLC method for determination of inosine and hypoxanthine in human plasma from healthy volunteers and patients presenting with potential acute cardiac ischemia.

Farthing D, Sica D, Gehr T, Wilson B, Fakhry I, Larus T, Farthing C, Karnes HT.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jul 1;854(1-2):158-64. Epub 2007 Apr 18.

PMID:
17466604
22.

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E; POWER 1 and 2 study groups.

Lancet. 2007 Apr 7;369(9568):1169-78. Erratum in: Lancet. 2008 Jan 12;371(9607):116.

PMID:
17416261
23.

A concise, convergent total synthesis of monocerin.

Cassidy JH, Farthing CN, Marsden SP, Pedersen A, Slater M, Stemp G.

Org Biomol Chem. 2006 Nov 21;4(22):4118-26.

PMID:
17312966
24.

Efficacy of an individualized adherence support program with contingent reinforcement among nonadherent HIV-positive patients: results from a randomized trial.

Javanbakht M, Prosser P, Grimes T, Weinstein M, Farthing C.

J Int Assoc Physicians AIDS Care (Chic). 2006 Dec;5(4):143-50.

PMID:
17101806
25.

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr, Steinhart CR, Trottier B, Walmsley SL, Workman C, Mukwaya G, Kohlbrenner V, Dohnanyi C, McCallister S, Mayers D; RESIST-1 Study Group.

Clin Infect Dis. 2006 Nov 15;43(10):1337-46. Epub 2006 Oct 17.

PMID:
17051503
26.

Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.

Khanlou H, Farthing C.

AIDS Patient Care STDS. 2006 Sep;20(9):604-5. No abstract available.

PMID:
16987045
27.

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.

DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Zhong L, Cheng AK, McColl D, Kearney BP; 183-0101 Study Team.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):1-5.

PMID:
16936557
28.

The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients.

Khanlou H, Sanchez S, Babaie M, Chien C, Hamwi G, Ricaurte JC, Stein T, Bhatti L, Denouden P, Farthing C.

Arch Intern Med. 2006 Jul 10;166(13):1417. No abstract available.

PMID:
16832008
29.

Molecular mechanisms controlling the coupled development of myocardium and coronary vasculature.

Bhattacharya S, Macdonald ST, Farthing CR.

Clin Sci (Lond). 2006 Jul;111(1):35-46. Review.

PMID:
16764556
30.

Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.

Khanlou H, Bhatti L, Farthing C.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):124-5. No abstract available.

PMID:
16340485
31.

Simple HPLC-UV method for determination of iohexol, iothalamate, p-aminohippuric acid and n-acetyl-p-aminohippuric acid in human plasma and urine with ERPF, GFR and ERPF/GFR ratio determination using colorimetric analysis.

Farthing D, Sica DA, Fakhry I, Larus T, Ghosh S, Farthing C, Vranian M, Gehr T.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 5;826(1-2):267-72. Epub 2005 Oct 5.

PMID:
16169291
32.

Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.

Khanlou H, Farthing C.

J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):503. No abstract available.

PMID:
16010179
33.

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.

Lori F, Pollard RB, Whitman L, Bakare N, Blick G, Shalit P, Foli A, Peterson D, Tennenberg A, Schrader S, Rashbaum B, Farthing C, Herman D, Norris D, Greiger P, Frank I, Groff A, Lova L, Asmuth D, Lisziewicz J.

AIDS Res Hum Retroviruses. 2005 Apr;21(4):263-72.

PMID:
15943568
35.

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients.

Khanlou H, Guyer B, Farthing C.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):627-8. No abstract available.

PMID:
15793377
36.

Tipranavir: a novel second-generation nonpeptidic protease inhibitor.

Kandula VR, Khanlou H, Farthing C.

Expert Rev Anti Infect Ther. 2005 Feb;3(1):9-21. Review. Erratum in: Expert Rev Anti Infect Ther. 2005 Apr;3(2):312.

PMID:
15757454
37.

Cited2 controls left-right patterning and heart development through a Nodal-Pitx2c pathway.

Bamforth SD, Bragança J, Farthing CR, Schneider JE, Broadbent C, Michell AC, Clarke K, Neubauer S, Norris D, Brown NA, Anderson RH, Bhattacharya S.

Nat Genet. 2004 Nov;36(11):1189-96. Epub 2004 Oct 10.

PMID:
15475956
38.

Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.

DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, Schrader SR, Castillo SA, Sension MG, Gough K, Madison SJ; EPV20001 International Study Team.

Clin Infect Dis. 2004 Aug 1;39(3):411-8. Epub 2004 Jul 15.

PMID:
15307010
39.

Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.

Fischl MA, Burnside AE Jr, Farthing CE, Thompson MA, Bellos NC, Williams VC, Kauf TL, Wannamaker PG, Shaefer MS; ESS40005 Study Team.

Pharmacotherapy. 2003 Nov;23(11):1432-40.

PMID:
14620390
40.

Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.

Rawlings MK, Thompson MA, Farthing CF, Brown LS, Racine J, Scott RC, Crawford KH, Goodwin SD, Tolson JM, Williams VC, Shaefer MS; NZTA4006 Helping to Enhance Adherence to Antiretroviral Therapy (HEART) Study Team.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):174-83.

PMID:
14526206
41.

Pilot study of directly observed therapy in highly nonadherent HIV-infected patients in an urban community-based institution.

Khanlou H, Kandula VR, Yeh V, Stein TG, Sanchez S, Ricaurte JC, Bhatti L, Farthing CF.

J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):651-3. No abstract available. Erratum in: J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):536. Ricuarte, Juan Carlos [corrected to Ricaurte, Juan Carlos].

PMID:
12902813
42.

High-resolution imaging of normal anatomy, and neural and adrenal malformations in mouse embryos using magnetic resonance microscopy.

Schneider JE, Bamforth SD, Farthing CR, Clarke K, Neubauer S, Bhattacharya S.

J Anat. 2003 Feb;202(2):239-47.

43.

Rapid identification and 3D reconstruction of complex cardiac malformations in transgenic mouse embryos using fast gradient echo sequence magnetic resonance imaging.

Schneider JE, Bamforth SD, Farthing CR, Clarke K, Neubauer S, Bhattacharya S.

J Mol Cell Cardiol. 2003 Feb;35(2):217-22.

PMID:
12606262
44.

Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.

Wheat LJ, Farthing C, Cohen C, Pierone G, Lalezari J, Pilson RS, Siemon-Hryczyk P; TIDBID (NR15520/M61018) study team.

Antivir Ther. 2002 Sep;7(3):199-209.

PMID:
12487388
45.

Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.

Khanlou H, Graham E, Brill M, Farthing C.

AIDS. 2002 Mar 29;16(5):797-8. No abstract available.

PMID:
11964539
46.

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM; VIRA3001 Study Team.

AIDS. 2002 Mar 8;16(4):579-88.

PMID:
11873001
47.

Heterogeneity of patients' adherence profile to antiretroviral therapy in HIV-infected patients.

Kennedy BL, O'Malley J, Khanlou H, Farthing C.

J Acquir Immune Defic Syndr. 2001 Nov 1;28(3):307-8. No abstract available.

PMID:
11694843
48.

Evaluation of a hydrogen peroxide disinfectant for dental unit waterlines.

Linger JB, Molinari JA, Forbes WC, Farthing CF, Winget WJ.

J Am Dent Assoc. 2001 Sep;132(9):1287-91.

PMID:
11665356
49.

A necessary risk: why we doctors should volunteer to try an AIDS vaccine.

Farthing CF.

Washington Post. 1997 Oct 19:C1, C6. No abstract available.

PMID:
11647305
50.

Many patients suffer from 'battle fatigue': survey.

Farthing CF.

AIDS Alert. 2001 Jun;16(6):73-7, 70.

PMID:
11569967

Supplemental Content

Loading ...
Support Center